| Affiliation: | 1. Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;2. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA;3. Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;4. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;5. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;1. Department of Pharmacy, National Hospital Organization Beppu Medical Center, 1473 Uchikamado, Beppu City, Oita 874-0011, Japan;2. Department of Pharmacy, National Hospital Organization Kumamoto Saisyunsou Hospital, 2659 Suya, Goushi City, Kumamoto 861-1196, Japan;3. Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, 2630 Sugitani, Toyama City, Toyama 930-0194, Japan;1. Department of Neurology, University Hospital of Cologne, Cologne, Germany;2. Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany;1. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia;2. Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, SA, Australia;3. Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, QLD, Australia;4. Department of Intensive Care Medicine, Royal Brisbane and Women''s Hospital, Brisbane, QLD, Australia;5. Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Adelaide, SA, Australia;6. Pharmacy Department, Royal Brisbane and Women''s Hospital, Brisbane, QLD, Australia;7. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK;1. Endowed Research Division of Human Welfare Sciences, Ochanomizu University, Tokyo, Japan;2. Institute for Human Life Innovation, Ochanomizu University, Tokyo, Japan |
